Research satisfaction among participants in a preclinical Alzheimer’s disease trial

by Clinical Neuropsychologist Online | Tuesday, September 22, 2026 | Dementia

Abstract INTRODUCTION Empirical data capturing participants’ experiences in preclinical Alzheimer’s disease (AD) trials are limited. We examined participant responses on a Research Satisfaction Survey (RSS) from the Anti-Amyloid Treatment in Asymptomatic AD...

Mendelian randomization evidence refines retinal alterations in Alzheimer’s disease

by Clinical Neuropsychologist Online | Tuesday, September 22, 2026 | Dementia

Alzheimer’s &Dementia, Volume 22, Issue 9, September 2026. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | September 22, 2026 Neuro-Dementia...

The Alzheimer’s disease risk gene SORL1 is a regulator of excitatory neuronal function

by Clinical Neuropsychologist Online | Tuesday, September 22, 2026 | Dementia

Abstract INTRODUCTION Synaptic dysfunction is an early feature of Alzheimer’s disease (AD) and proper localization of proteins involved in pre- and post-synaptic composition is dependent on endosomal recycling and trafficking, cellular processes involving the AD...

Enhancing early Alzheimer’s disease clinical trials through prognostic score covariate adjustment

by Clinical Neuropsychologist Online | Tuesday, September 22, 2026 | Dementia

Abstract INTRODUCTION A prognostic score (PS) summarizes a patient’s expected disease progression and can increase the statistical efficiency of clinical trials when included as an analysis covariate. METHODS We pooled patient data from observational studies and...

Changes in serum β‐synuclein precede blood biomarkers of Alzheimer pathology in Down syndrome

by Clinical Neuropsychologist Online | Tuesday, September 22, 2026 | Dementia

Abstract INTRODUCTION There is a need for early, objective markers of Alzheimer’s disease (AD)-related synapse dysfunction in adults with Down syndrome (DS). The presynaptic protein β-synuclein is elevated in the blood of adults with DS. This study evaluates the...

Unmasking preclinical Alzheimer’s pathology: auditory distraction cost and occupational reserve jointly discriminate amyloid positivity in subjective cognitive decline

by Clinical Neuropsychologist Online | Tuesday, September 22, 2026 | Dementia

Abstract INTRODUCTION Conventional cognitive instruments exhibit limited efficacy in detecting insidious cognitive decline in subjective cognitive decline (SCD) due to neural compensation. We hypothesized that auditory distraction during a visual memory task would...